ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
18 oct. 2023 07h05 HE
|
ZyVersa Therapeutics
Inflammasome NLRP3 activation is associated with an age-related decline in kidney health, which is compounded in the presence of kidney disease.
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
27 sept. 2023 07h07 HE
|
ZyVersa Therapeutics
Mr. Glover will also serve as a judge in BioPitch competition for life science companies seeking seed and early-stage investment.ZyVersa is advancing a dynamic pipeline of drug candidates with...
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
17 juil. 2023 07h38 HE
|
ZyVersa Therapeutics
Liver fibrosis is a progressive form of chronic liver injury mediated by persistent NLRP3 inflammasome activation in liver cells called hepatic stellate cells (“HSCs”), which leads to the development...
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
26 avr. 2023 08h10 HE
|
Invea Therapeutics
GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
06 déc. 2022 08h10 HE
|
Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...
Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
25 janv. 2021 09h00 HE
|
Neuropathix, Inc.
DOYLESTOWN, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB: NPTX), a socially responsible pain management life sciences company, announced today...
The Next Generation of Innovative Immunotherapy Agents, Inflammasome Inhibitors, Will Be Addressed in Panel Discussion on Monday, Feb. 17, 2020, at 10 a.m. EST
10 janv. 2020 11h50 HE
|
Noble Capital Markets, Inc.
FORT LAUDERDALE, Fla., Jan. 10, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- Noble Capital Markets, Inc. (“Noble”) announced it has assembled a panel of scientists and experienced life science...